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Background: Reducing socioeconomic inequalities in lung cancer treatment may reduce survival inequalities. However, the
reasons for treatment variation are unclear.
Methods: Northern and Yorkshire cancer registry, Hospital Episode Statistics and lung cancer audit data sets were linked.
Logistic regression was used to explore the role of stage, histology, performance status and comorbidity in socioeconomic
inequalities in lung cancer treatment, for 28 733 lung cancer patients diagnosed in 2006–2010, and in a subgroup with stage
recorded (n¼ 7769, 27%).
Results: Likelihood of receiving surgery was significantly lower in the most deprived group (odds ratio (OR)¼ 0.75, 95% confidence
interval (CI) 0.65–0.86); however, the OR was attenuated when including histological subtype (OR¼ 0.82, 95% CI 0.71–0.96).
Patients in the most deprived group were significantly less likely to receive chemotherapy in the fully adjusted full cohort model
including performance status (OR¼ 0.64, 95% CI 0.58–0.72) but not in the staged subgroup model when performance status was
included (OR¼ 0.88, 95% CI 0.72–1.08). Socioeconomic inequalities in radiotherapy were not found.
Interpretation: Socioeconomic inequalities in performance status statistically explained socioeconomic inequalities in receipt of
chemotherapy in the selective staged subgroup, but not in the full cohort. Socioeconomic variation in histological subtype may
account for some of the socioeconomic inequalities in surgery.
In England, less than 10% of those diagnosed with lung cancer
survive for 5 years (Coleman et al, 2011). Lung cancer patients of
lower socioeconomic position (SEP) have poorer survival (Rachet
et al, 2010). It has been suggested that socioeconomic differences in
receipt of cancer treatment might at least partially contribute to
survival inequalities (Woods et al, 2006). There is some evidence
that socioeconomic inequalities in lung cancer survival can be
statistically explained by inequalities in treatment (Jack et al, 2006;
Forrest et al, 2013b).
Socioeconomic inequalities in receipt of lung cancer surgery and
chemotherapy, but not radiotherapy, were found in both universal
(UHCS) and non-universal health-care systems, in a recent
systematic review and meta-analysis (Forrest et al, 2013a). These
findings could not be explained by the type of health-care system
or by socioeconomic inequalities in stage at diagnosis. However,
not all of the studies included in the review reported details of stage
and histology, both of which influence treatment type (Forrest
et al, 2013a), and very few took comorbidity into account. The
review authors recommended that the reasons for socioeconomic
inequalities in treatment should be more thoroughly investigated in
studies including statistical control for comorbidity, stage and
histology (Forrest et al, 2013a).
Performance status (PS), a global measure of functional status
and an important consideration for clinicians treating lung cancer
(NICE, 2005), is a factor that has not previously been well explored
in studies examining socioeconomic inequalities in treatment.
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Although comorbidity and PS measure different things (the
number of concurrent health conditions over a period of time
before cancer diagnosis and general health status at the time of
lung cancer diagnosis, respectively), both variables may be used as
surrogate measures of suitability for treatment (Ludbrook et al,
2003). It is unclear how well comorbidity and PS capture fitness for
treatment but, as the number of comorbidities varies by SEP for
cancer patients (Louwman et al, 2010), this may help to explain
inequalities in treatment.
Lung cancers are broadly classified into small cell (SCLC) and
non-small cell (NSCLC) cancers, with NSCLC accounting for
B80% of lung cancers. Non-small cell lung cancer can be further
divided into squamous cell carcinoma, adenocarcinoma and large
cell carcinoma subtypes (NICE, 2005). Squamous cell carcinoma is
strongly associated with smoking, as is SCLC (Hirsch et al, 2008).
Adenocarcinomas are a morphologically heterogeneous group and,
although they are associated with smoking (Sharpe et al, 2012),
they are also found in those who have never smoked, particularly
in women (Hirsch et al, 2008). As SEP is associated with smoking
and with histological subtype (Sharpe et al, 2012), histological
subtype may confound the relationship between SEP and treatment
for lung cancer.
In this study, we linked Northern and Yorkshire Cancer
Registry and Information Centre (NYCRIS), Hospital Episode
Statistics (HES) and National Lung Cancer Audit (LUCADA) data
sets in order to examine the factors that may help to explain
socioeconomic inequalities in lung cancer treatment (surgery,
chemotherapy and radiotherapy). The role of stage, histology
(and, within this, histological subtype), PS and comorbidity in
statistically explaining socioeconomic inequalities in lung cancer
treatment was specifically explored.
MATERIALS AND METHODS
Data sources. The Northern and Yorkshire Cancer Registry is one
of eight English regional cancer registries that collect a common
minimum cancer data set (NYCRIS, 2012). Data on SEP, age, sex,
histology, tumour, year of diagnosis, GP referral and details of
receipt of treatment (surgery, chemotherapy and radiotherapy)
were obtained from registry data. Comorbidity data were obtained
from HES.
Incomplete recording of stage data is a major limitation of UK
cancer registry data. However, stage data are collected by the
LUCADA, a non-mandatory register of clinical information on
patients diagnosed with lung cancer in the United Kingdom. The
audit initially included only a subset of registry patients (66%
nationally in 2006, increasing to 93% in 2010; NHS Information
Centre, 2012).
Records were allocated a unique, randomly generated, key
number, derived from the NHS number by NYCRIS. Data from the
three data sources (NYCRIS cancer registry, HES and LUCADA
data) were anonymised and supplied by NYCRIS. The HES and
LUCADA data were then linked to the regional registry data using
key numbers.
Variables of interest. Socioeconomic position was measured
using the agreed methodology for all English cancer registries,
the rank of the income domain of the Index of Multiple
Deprivation (IMD). This is an area-based measure of SEP (HM
Government, 2013), grouped into quintiles, where Q5 is the most
deprived and Q1 the least deprived. The England-wide distribution
of IMD was used. This is periodically updated to allow inclusion of
the most recent data. The income domain of IMD2010 was used
for patients diagnosed between 2007 and 2010. For those diagnosed
in 2006 the income domain of IMD2007 was used.
Age at diagnosis was categorised into four groups: age o60,
60–69, 70–79 and 80þ years. Year of diagnosis was included
to take into account changes in rates of treatment over time.
GP referral was categorised as yes or no.
Lung cancer was categorised into the following eight histological
subtypes: adenocarcinoma, large cell carcinoma, non-small cell
carcinoma, squamous cell carcinoma, small cell carcinoma, other
specified carcinoma, unspecified carcinoma (Riaz et al, 2012) and
neoplasm. Lung cancer histology was classified as NSCLC,
including adenocarcinoma, large cell carcinoma, non-small cell
carcinoma and squamous cell carcinoma subtypes; SCLC; and
other histology (including unspecified carcinoma, neoplasm
and other specified carcinomas (including carcinoid tumours)),
using ICD-0-3 morphology codes to categorise histological
subtypes (WHO (World Health Organisation), 2000). When
examining NSCLC and SCLC separately, the unspecified
carcinoma and neoplasm subtypes were excluded and the other
specified carcinoma subtype was included as probable NSCLC
(Riaz et al, 2012).
A weighted comorbidity score was calculated by NYCRIS using
the Charlson comorbidity index (CCI; Charlson et al, 1987) using
the number of in-patient HES admissions for 16 specified
conditions (excluding metastatic cancer) in the 3–18 months
before diagnosis. HES-linked comorbidity data were not available
for patients diagnosed in 2009–2010 as, because of national
problems in calculating the comorbidity score, there was a time lag
in data availability. Comorbidity score was categorised as 0, 1–2,
3þ , missing or unavailable.
Stage and PS data were obtained from LUCADA. Stage was
assigned using the TNM staging system (Sobin and Wittekind,
1997) and categorised as I, II, III, IV or missing. Performance
status at the time of lung cancer diagnosis was recorded on a scale
of 0 (asymptomatic) to 4 (bedridden) using the Eastern
Cooperative Group PS scale (NICE, 2005) and categorised as 0,
1–2, 3–4 or missing.
Analysis. Data for 29 385 patients with a primary diagnosis of
lung cancer (ICD10 C33 and C34), diagnosed between 1 January
2006 and 31 December 2010, were obtained. Of these, 652 had
tumour registration based on death-certification only and were
excluded from analyses, leaving an eligible cohort of 28 733.
The distribution of stage, histological subtype, PS and
comorbidity by SEP was examined using w2 tests. The distribution
of each variable in the subgroup that had stage recorded (n¼ 7769)
was compared with that in the full cohort using w2 tests to
determine the representativeness of the subgroup.
Univariable and multivariable logistic regressions were used
to examine the likelihood of receipt of each of three treatments –
surgery, chemotherapy and radiotherapy, at any time after
diagnosis – by SEP, in the full cohort and the staged subgroup.
Receipt of surgery was also examined for probable NSCLC-only
patients (n¼ 16 278). Recipients of chemotherapy and radio-
therapy were examined separately in probable NSCLC
(n¼ 16 278) and SCLC (n¼ 3495) populations. Age, sex,
histology (or histological subtype), year of diagnosis, GP
referral, comorbidity, PS and stage (where available) were
controlled for in fully adjusted models. A forward stepwise
approach was used to explore which variables were important in
explaining socioeconomic inequalities in treatment. The R2
statistic was examined as a measure of model fit, to determine
the amount (%) of variance in receipt of treatment explained by
each model. Odds ratios (ORs) with 95% confidence intervals
(CIs) for the likelihood of receipt of treatment in each SEP
quintile compared with the least deprived were reported.
A likelihood ratio test was performed to determine the overall
significance of each categorical variable. Analysis was carried
out in Stata v12.0 (StataCorp, College Station, TX, USA).
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RESULTS
Table 1 shows the demographic and clinical characteristics of the
cohort. Of the 28 733 patients included in the full cohort analysis,
7769 (27%) had stage and 8885 (31%) had a PS score recorded in
LUCADA, and 8475 (29%) had a comorbidity score ascertained
from HES. There were significant differences between the full
cohort and the staged subgroup in the distribution of age group,
histology, comorbidity and receipt of treatment, but not SEP or
sex. The staged subgroups were younger, had a higher proportion
of NSCLC patients and a higher proportion receiving treatment.
Significant differences in distribution of PS, number of comorbid-
ities and histology, but not stage at diagnosis, were seen by SEP.
A higher proportion of more deprived patients had poor PS,
more comorbidity and a squamous cell histological subtype
(Supplementary Table 1).
Surgery. In the full cohort, the odds of receipt of surgery were
significantly lower in the most compared to the least deprived
group in the unadjusted analysis (OR¼ 0.78, 95% CI 0.69–0.89)
and in the fully adjusted multivariable analysis (OR¼ 0.75, 95% CI
0.65–0.86). When histology was further broken down into
histological subtypes then the SEP OR was attenuated
(OR¼ 0.82, 95% CI 0.71–0.96) (Table 2) and the amount of
outcome variance explained by the model greatly increased (from
R2¼ 24.32% to 35.29%).
A similar result was seen for receipt of surgery in the most,
compared with the least, deprived group in patients with probable
NSCLC (OR¼ 0.84, 95% CI 0.72–0.98; Supplementary Table 2),
and in the subgroup that had stage recorded (OR¼ 0.61,
95% CI 0.44–0.83; Supplementary Table 3).
Chemotherapy. Socioeconomic position was associated with
receipt of chemotherapy in the fully adjusted full cohort model
(OR¼ 0.61, 95% CI 0.55–0.68). The inclusion of histological
subtype rather than histology only marginally attenuated the odds
ratio (OR¼ 0.64, 95% CI 0.58–0.72; Table 3).
In the subgroup of patients who had stage recorded, no
statistically significant association between SEP and receipt of
chemotherapy was found in the unadjusted analysis (OR¼ 0.86,
95% CI 0.73–1; Table 4) but was seen in a multivariable analysis
including age, sex, histological subtype, year of diagnosis, GP
referral, CCI score and stage (OR¼ 0.73, 95% CI 0.60 to 0.88).
However, on the addition of PS to the model the OR was
attenuated and this association was no longer significant
(OR¼ 0.88, 95% CI 0.72–1.08; Table 4). Including PS also
increased the model fit (R2¼ 28.04% without PS, 35.86% with).
When chemotherapy was examined separately in probable
NSCLC and SCLC populations, socioeconomic inequalities in
receipt of chemotherapy were found for NSCLC (OR¼ 0.67,
95% CI 0.59–0.76; Supplementary Table 4) and SCLC (OR¼ 0.57,
95% CI 0.43–0.75; Supplementary Table 5). For NSCLC patients,
the likelihood of chemotherapy increased over time but this was
not seen for SCLC.
Radiotherapy. No association between SEP and receipt of radio-
therapy was found in the full cohort in the fully adjusted model
including histology (OR¼ 1.03, CI 0.95–1.13) or histological
subtype (OR¼ 1.02, CI 0.93–1.11; Table 5). Similar results were
found in the subgroup of patients who had stage recorded
(OR¼ 1.01, 95% CI 0.86–1.19). Different patterns of results were
seen when receipt of radiotherapy was examined separately in
probable NSCLC (OR¼ 1.11, 95% CI 1–1.24) (Supplementary
Table 6) and SCLC (OR¼ 0.84, 95% CI 0.66–1.07; Supplementary
Table 7) populations, but again were nonsignificant.
DISCUSSION
Principal findings. This is one of the first UK registry-based
studies to include a wide range of confounders and potentially
important explanatory factors including stage, histology, comor-
bidity and PS, in order to determine their influence on socio-
economic inequalities in lung cancer treatment. In this study, we
found socioeconomic inequalities in the receipt of surgery and
chemotherapy, but not radiotherapy, for lung cancer, in the full
cohort analyses. Having taken all the above factors into account,
socioeconomic inequalities in receipt of surgery persisted. How-
ever, socioeconomic inequalities in receipt of chemotherapy were
not found in the staged subgroup on addition of PS to the stepwise
model.
Socioeconomic differences in PS statistically accounted for
much of the socioeconomic inequality in receipt of chemotherapy
in the staged subgroup. Socioeconomic differences in histological
subtype may partially account for some of the observed socio-
economic differences in receipt of surgery observed.
Strengths and limitations. The use of multiple data set linkage
(NYCRIS cancer registrations, HES and LUCADA) allowed us to
include a broader range of potential confounders than previous
UK registry studies (Jack et al, 2006; Berglund et al, 2012). Only
two other UK studies (using early-year LUCADA audit data)
have included PS in a multivariable analysis of receipt of lung
cancer treatment (Rich et al, 2011a, b). We were able to include
later years of LUCADA data (2009–2010), which are more
complete.
The population-based approach and the completeness and
validity of the cancer registry data are the strengths of this study,
although there may be some under-reporting of chemotherapy and
radiotherapy treatments within registry data sets (Riaz et al, 2010).
We used data from the north of England that may limit the
generalisability of the findings to other locations. The high level of
missing data for some variables is also a major limitation. Multiple
imputation was considered but is not recommended, where over
50% of values for a variable are missing (White et al, 2011).
To address the problem of missing data, we analysed complete-case
data for the subset of patients who had stage recorded (the majority
of whom also had PS recorded). As results from complete-case
analyses can be biased (Sterne et al, 2009) we also analysed the
full cohort and included missing categories for stage, PS and
comorbidity, although this too can result in bias.
The validity of PS and CCI score as proxy measures of patients
well-being is unclear. Performance status is a measure of patients
acute functional status and need for care, assigned on a scale of 0–4
by the care team. Only moderate agreement in allocating PS score
was found in an interobserver reliability study (Sorensen et al,
1993). However, there was good agreement when allocating good
(PS 0–2) compared with poor PS (PS 3–4), which were similar to
the groupings we employed.
The Charlson comorbidity index is a validated instrument for
measuring comorbidity (Charlson et al, 1987) over a longer period
of time. However, it may underestimate comorbidity as patients
who suffer from a relevant condition but are treated entirely in
primary care score zero. It has also been suggested that it is a crude
measure of comorbidity, as patients with mild and severe forms of
a disease receive the same score (Berglund et al, 2012). This could
be a problem for conditions such as chronic pulmonary obstructive
disease, where the severity of the disease is likely to influence the
likelihood of receiving surgery for lung cancer. However, the index
only contains details of conditions that are serious enough to
require in-patient care.
Interpretation of results and comparison with other studies.
Socioeconomic inequalities in receipt of surgery may be partially
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Table 1. Demographic and clinical characteristics of full cohort and staged subgroup
Full cohort Staged subgroup
Variable N % N % v2 P
Deprivation quintile 28 733 100 7769 100 0.86 0.930
1 (Least deprived) 3389 11.8 931 12.0
2 4178 14.5 1118 14.4
3 4848 16.9 1300 16.7
4 6710 23.4 1831 23.6
5 (Most deprived) 608 33.4 2589 33.3
Sex 28 733 100 7769 100 0.44 0.511
Female 13 254 46.1 3559 45.8
Male 15 479 53.9 4210 54.2
Age group 28 733 100 7769 100 62.65 o0.001
o60 3682 12.8 1041 13.4
60–69 7595 26.4 2189 28.2
70–79 10 248 35.7 2843 36.6
80þ 7208 25.1 1696 21.8
Year of diagnosis 28 733 100 7769 100 2.1eþ0.3 o0.001
2006 5533 19.3 671 8.6
2007 5712 19.9 866 11.2
2008 5851 20.4 1556 20.0
2009 5871 20.4 2140 27.6
2010 5766 20.1 2536 32.6
Comorbidity score 28 733 100 7769 100 39.02 o0.001
0 4010 14.0 995 12.8
1–2 3531 12.3 857 11.0
3þ 934 3.3 226 2.9
Missing 10 175 35.4 1977 25.5
Unavailable 10 083 35.1 3714 47.8
Stage 28 733 100 7769 100 2.9eþ0.4 o0.001
I 1186 4.1 1186 15.3
II 552 1.9 552 7.1
III 2273 7.9 2273 29.3
IV 3758 13.1 3758 48.4
Missing 20 964 73.0 — —
Performance status 28 733 100 7769 100 1.8eþ0.4 o0.001
0 1842 6.4 1493 19.2
1–2 4865 16.9 3870 49.8
3–4 2178 7.6 1763 22.7
Missing 19 848 69.1 643 8.3
GP referral 28 733 100 7769 100 976.52 o0.001
Yes 15 452 53.8 5351 68.9
No 13 281 46.2 2418 31.1
Histology 28 733 100 7769 100 765.53 o0.001
NSCLC 15 123 52.6 5116 65.9
SCLC 3495 12.2 582 7.5
Other 10 115 35.2 2071 26.7
Histological subtype 28 733 100 7769 100 849.92 o0.001
Adenocarcinoma 4462 15.5 1473 19.0
Squamous cell 5229 18.2 1850 23.8
Large cell 768 2.7 169 2.2
Non-small cell 4664 16.2 1624 20.9
Small cell 3495 12.2 582 7.5
Other specified 1155 4.0 298 3.8
Unspecified carcinoma 520 1.8 93 1.2
Neoplasm 8440 29.4 1680 21.6
Socioeconomic inequalities in lung cancer care BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.310 611
explained by socioeconomic differences in histological subtype.
We found a significant association between SEP and histological
subtype, with a lower proportion of squamous cell and higher
proportion of adenocarcinoma subtype (and higher rates of
treatment in this latter subtype) in the least deprived compared
with most deprived group. A previous UK lung cancer study found
that adenocarcinoma was less clearly associated with deprivation
than other histological subtypes, possibly as it is less strongly
associated with smoking (Bennett et al, 2008), and smoking is
strongly socioeconomically patterned. It may be that health factors
relating to smoking, rather than histological subtype, help to
determine receipt of surgery, and we cannot rule out uncontrolled
confounding related to smoking status. It is likely that smokers
have generally poorer health and, although we were able to include
PS and CCI score in the analysis, these measures may not fully
capture this.
In agreement with the results from our systematic review of
socioeconomic inequalities in lung cancer treatment (Forrest
et al, 2013a), we found socioeconomic inequalities in receipt of
surgery, and these remained after inclusion of stage, PS and
comorbidity. In contrast, the only two other UK studies that
included PS in a multivariable analysis of receipt of treatment,
using national LUCADA data, found no association between SEP
and receipt of surgery but did find an association with receipt of
chemotherapy (Rich et al, 2011a, b). We also found that, when
including PS, SEP remained associated with a lower likelihood of
receipt of chemotherapy in the full cohort but that SEP was no
longer associated with receipt of chemotherapy in the staged
subgroup.
The first few years of LUCADA data included only a small
subset of registry patients and there were significant differences in
stage at diagnosis, histology and PS when comparing patients from
hospital Trusts with high levels of missing data with those who had
low levels (Rich et al, 2011b). The validity of the pre-2007
LUCADA data has also been queried due to the poor entry of
staging data (Murdoch et al, 2010). It may be that patients included
in LUCADA in the early years of the audit are not representative of
the full spectrum of patients diagnosed with lung cancer in
England and this may explain the different pattern of results found
using early audit data compared with studies using registry data.
Concordance of recording of data on receipt of chemotherapy in
LUCADA compared with registry data is reportedly poor, with
48% of patients with chemotherapy recorded in national registry
data having no record of chemotherapy in LUCADA (Riaz et al,
2010); therefore, again this might account for some of the
differences found.
Socioeconomic inequalities in receipt of radiotherapy were not
found, although different patterns were seen for NSCLC
compared with SCLC, when examined separately. It was not
possible to distinguish between palliative and radical radio-
therapy. Low-dose palliative radiotherapy is most commonly
given, whereas fewer than 10% of patients receive high-dose
radiotherapy with potentially curative intent. It is possible that
differential effects by SEP might be seen if treatment-intent
was examined, with more deprived SEP patients more likely
to get palliative radiotherapy, and less deprived patients are
likely to get curative radiotherapy. Potentially, these differential
effects could effectively cancel each other out in statistical
analyses and might help to explain why no overall association
was found.
Implications for policy and practice. In this study, a higher
percentage of more deprived patients had a squamous cell subtype
that is strongly associated with smoking, although we were unable
to measure smoking status in this cohort. Surgery rates were also
lower for this histological subtype. Non-smokers are less likely to
develop lung cancer and if they do then it may be that they are
more likely to have a histological subtype that is more amenable
to surgery. This is a further reason, if any other were required,
to continue to promote aggressive antismoking and smoking-
cessation campaigns.
The guidelines indicate that chemotherapy should be offered to
stage III NSCLC patients and to stage IV patients with good PS
(NICE, 2005). Socioeconomic differences in PS may determine
whether a patient receives chemotherapy. Although there is a long
chain of causality from health behaviours earlier in life to health
status in later life, healthy behaviours should be encouraged, as
patients who are in better health are likely to have a greater chance
of receiving chemotherapy. It is unclear whether making lifestyle
changes once diagnosed with cancer is likely to do much to
improve PS, although a recent systematic review and meta-analysis
produced preliminary evidence for improved survival for early-
stage lung cancer patients who quit smoking after diagnosis
(Parsons et al, 2010).
We were unable to take patient choice into account. Poorer
health literacy may influence patient choice and understanding of
risk, and this may vary by SEP (Protheroe et al, 2013), as might
more fatalistic attitudes and health beliefs. If patients have poor
capacity to process and understand basic health information, then
they are less able to make appropriate health and treatment
decisions (Nutbeam, 2008). It is important that clinicians take this
into account when discussing treatment options.
Table 1. ( Continued )
Full cohort Staged subgroup
Variable N % N % v2 P
Receipt of surgery 28 733 100 7769 100 92.99 o0.001
Yes 2894 10.1 1001 12.9
No 25 839 89.9 6768 87.1
Receipt of chemotherapy 28 733 100 7769 100 192.96 o0.001
Yes 8348 29.1 2732 35.2
No 20 385 70.9 5037 64.8
Receipt of radiotherapy 28 733 100 7769 100 175.30 o0.001
Yes 9611 33.4 3069 39.5
No 19 122 66.6 4700 60.5
Abbreviations: CCI score¼Charlson comorbidity score; CI¼ confidence interval; IMD¼ Index of Multiple Deprivation; NSCLC¼non-small cell lung cancer; OR¼odds ratio; SCLC¼ small cell
lung cancer. w2¼ w2 for difference in variable distribution between full cohort and staged subgroup.
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Table 2. Likelihood of receipt of lung cancer surgery, by SEP, adjusted for selected patient, tumour and system factors, for full cohort
Receipt of surgery
(2894/28733) Unadjusted (n¼28733)
Adjusted – sex, age, year, CCI, GP referral,
stage, PS, histological subtype (n¼28733,
R2¼35.29%)
Variable N % OR (95% CI) P OR (95% CI) P
Deprivation quintile 2894 10.1 o0.001 0.01
1 (Least deprived) 400 11.8 1.00
2 458 11.0 0.92 0.80 1.06 0.91 0.77 1.08
3 512 10.6 0.88 0.77 1.01 0.97 0.82 1.15
4 613 9.1 0.75 0.66 0.86 0.80 0.68 0.94
5 (Most deprived) 911 9.5 0.78 0.69 0.89 0.82 0.71 0.96
Sex 2894 10.1 o0.001
Female 1405 10.6 1.00
Male 1489 9.6 0.78 0.71 0.85
Age group 2894 10.1 o0.001
o60 560 15.2 1.00
60–69 1118 14.7 1.04 0.92 1.19
70–79 1048 10.2 0.79 0.69 0.90
80þ 168 2.3 0.22 0.18 0.26
Year of diagnosis 2894 10.1 o0.001
2006 505 9.1 1.00
2007 547 9.6 1.10 0.95 1.27
2008 502 8.6 0.96 0.83 1.12
2009 682 11.6 1.50 1.31 1.88
2010 658 11.4 1.58 1.29 1.92
CCI score 2894 10.1 0.0002
0 482 12.0 1.00
1–2 326 9.2 0.90 0.75 1.07
3þ 83 9.0 1.01 0.75 1.36
Missing 1021 10.0 0.91 0.79 1.06
Unavailable 982 9.7 0.69 0.58 0.81
GP referral 2894 10.1 o0.001
No 979 7.4 1.00
Yes 1915 12.4 1.27 1.15 1.40
Stage 2894 10.1 o0.001
I 607 51.2 1.00
II 195 35.3 0.43 0.33 0.56
III 144 6.3 0.04 0.04 0.06
IV 55 1.5 0.01 0.01 0.02
Missing 1893 9.0 0.11 0.09 0.14
Performance status 2894 10.1 o0.001
0 583 31.7 1.00
1–2 480 9.9 0.33 0.27 0.40
3–4 15 0.7 0.05 0.03 0.09
Missing 1816 9.2 0.41 0.34 0.50
Histological subtype 2894 10.1 o0.001
Adenocarcinoma 998 22.4 1.00
Squamous cell 1011 19.3 0.86 0.77 0.97
Large cell 124 16.2 0.64 0.51 0.80
Non-small cell 215 4.6 0.19 0.16 0.22
Other (specified) 470 40.7 2.40 2.06 2.80
Small cell 54 1.6 0.06 0.04 0.07
Unspecified carcinoma 14 2.7 0.14 0.08 0.25
Neoplasm 8 0.1 0.01 0.00 0.01
Abbreviations: CCI score¼Charlson comorbidity score; CI¼ confidence interval; IMD¼ Index of Multiple Deprivation; NSCLC¼ non-small cell lung cancer; OR¼odds ratio; PS¼performance
status; SCLC¼ small cell lung cancer; SEP¼ socioeconomic position.
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Table 3. Likelihood of receipt of lung cancer chemotherapy, by SEP, adjusted for selected patient, tumour and system factors, for full cohort
Receiving
chemotherapy
(8348/28733) Unadjusted (n¼28733)
Adjusted – sex, age, year, comorbidity
score, GP referral, stage, PS, histological
subtype (n¼28733, R2¼34.97%)
Variable N % OR (95% CI) P OR (95% CI) P
Deprivation quintile 8348 29.1 o0.001 o0.001
1 (least deprived) 1133 33.4 1.00 1.00
2 1275 30.5 0.87 0.79 0.96 0.85 0.75 0.96
3 1425 29.4 0.83 0.75 0.91 0.82 0.73 0.93
4 1898 28.3 0.79 0.72 0.86 0.70 0.63 0.79
5 (Most deprived) 2617 27.2 0.75 0.69 0.81 0.64 0.58 0.72
Sex 8348 29.1 0.43
Female 3810 28.8 1.00
Male 4538 29.3 1.03 0.96 1.10
Age group 8348 29.1 o0.001
o60 2221 60.3 1.00
60–69 3332 43.9 0.54 0.49 0.60
70–79 2452 23.9 0.24 0.22 0.27
80þ 343 4.8 0.05 0.05 0.06
Year of diagnosis 8348 29.1 o0.001
2006 1506 27.2 1.00
2007 1667 29.2 1.19 1.07 1.31
2008 1681 28.7 1.09 0.98 1.20
2009 1773 30.2 1.47 1.28 1.68
2010 1721 29.9 1.49 1.29 1.72
Comorbidity score 8348 29.1 o0.001
0 1224 30.5 1.00
1–2 669 19.0 0.67 0.59 0.77
3þ 122 13.1 0.50 0.39 0.63
Missing 3503 34.4 1.12 1.00 1.24
Unavailable 2830 28.1 0.76 0.67 0.85
GP referral 8348 29.1 o0.001
No 2566 19.3 1.00
Yes 5782 37.4 2.04 1.91 2.19
Stage 8348 29.1 o0.001
I 223 18.8 1.00
II 163 29.5 2.17 1.65 2.85
III 1032 45.4 5.77 4.71 7.06
IV 1314 35.0 4.49 3.69 5.46
Missing 5616 26.8 3.55 2.90 4.34
Performance status 8348 29.1 o0.001
0 1151 62.5 1.00
1–2 2067 42.5 0.49 0.43 0.56
3–4 113 5.2 0.04 0.03 0.05
Missing 5017 25.3 0.32 0.27 0.37
Histological subtype 8348 29.1 o0.001
Adenocarcinoma 1658 37.2 1.00
Squamous cell 1767 33.8 0.89 0.81 0.98
Large cell 271 35.3 0.94 0.79 1.12
Non-small cell 1670 35.8 0.97 0.88 1.07
Other (specified) 377 32.6 0.84 0.72 0.98
Small cell 2381 68.1 5.25 4.70 5.86
Unspecified carcinoma 66 12.7 0.36 0.27 0.49
Neoplasm 158 1.9 0.08 0.06 0.09
Abbreviations: CCI score¼Charlson comorbidity score; CI¼ confidence interval; IMD¼ Index of Multiple Deprivation; NSCLC¼ non-small cell lung cancer; OR¼odds ratio; PS¼performance
status; SCLC¼ small cell lung cancer; SEP¼ socioeconomic position.
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Differences in communication patterns between health profes-
sionals and patients by SEP have been described that may influence
the treatment prescribed (Murphy et al, 2010). Doctors may make
treatment decisions based on which patients they consider likely
to do well, using factors such as age, weight and comorbidity
(Dixon-Woods et al, 2006) and these judgements may disadvantage
Table 4. Likelihood of receipt of lung cancer chemotherapy, by SEP, adjusted for selected patient, tumour and system factors, for staged subgroup
Receiving
chemotherapy
(2732/7769) Unadjusted (n¼7769)
Adjusted – sex, age, year, CCI, GP referral,
stage, PS, histological subtype (n¼7769,
R2¼35.86%)
Variable N % OR (95% CI) P OR (95% CI) P
Deprivation quintile 2732 35.2 0.19 0.34
1 (Least deprived) 351 37.7 1.00 1.00
2 414 37.0 0.97 0.81 1.16 1.00 0.80 1.26
3 445 34.2 0.86 0.72 1.02 1.04 0.83 1.31
4 638 34.8 0.88 0.75 1.04 0.92 0.74 1.14
5 (Most deprived) 884 34.1 0.86 0.73 1.00 0.88 0.72 1.08
Sex 2732 35.2 0.78
Female 1255 35.3 1.00
Male 1477 35.1 1.02 0.90 1.15
Age group 2732 35.2 o0.001
o60 690 66.3 1.00
60–69 1103 50.4 0.57 0.48 0.69
70–79 821 28.9 0.27 0.22 0.32
80þ 118 7.0 0.06 0.05 0.08
Year of diagnosis 2732 35.2 0.03
2006 211 31.5 1.00
2007 323 37.3 1.48 1.13 1.93
2008 556 35.7 1.39 1.09 1.77
2009 758 35.4 1.46 1.09 1.95
2010 884 34.9 1.46 1.08 1.97
CCI score 2732 35.2 0.03
0 353 35.5 1.00
1–2 203 23.7 0.74 0.57 0.95
3þ 40 17.7 0.68 0.43 1.07
Missing 800 40.5 1.05 0.84 1.33
Unavailable 1336 36.0 0.92 0.74 1.15
GP referral 2732 35.2 o0.001
No 603 24.9 1.00
Yes 2129 39.8 1.98 1.72 2.28
Stage 2732 35.2 o0.001
I 223 18.8 1.00
II 163 29.5 2.26 1.71 2.98
III 1032 45.4 6.06 4.92 7.46
IV 1314 35.0 4.70 3.84 5.75
Performance status 2732 35.2 o0.001
0 933 62.5 1.00
1–2 1561 40.3 0.41 0.35 0.48
3–4 78 4.4 0.03 0.02 0.04
Missing 160 24.9 0.27 0.21 0.34
Histological subtype 2732 35.2 o0.001
Adenocarcinoma 652 44.3 1.00
Squamous cell 732 39.6 0.81 0.68 0.96
Large cell 73 43.2 0.96 0.65 1.41
Non-small cell 683 42.1 0.91 0.77 1.09
Other (specified) 110 36.9 0.85 0.63 1.16
Small cell 411 70.6 5.42 4.15 7.07
Unspecified carcinoma 19 20.4 0.45 0.24 0.84
Neoplasm 52 3.1 0.10 0.08 0.14
Abbreviations: CCI score¼Charlson comorbidity score; CI¼ confidence interval; IMD¼ Index of Multiple Deprivation; NSCLC¼ non-small cell lung cancer; OR¼odds ratio; PS¼performance
status; SCLC¼ small cell lung cancer; SEP¼ socioeconomic position.
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Table 5. Likelihood of receipt of lung cancer radiotherapy, by SEP, adjusted for selected patient, tumour and system factors, for full cohort
Receiving
radiotherapy (9611/
28733) Unadjusted (n¼28733)
Adjusted – sex, age, year, CCI, GP referral,
stage, PS, histological subtype (n¼28733,
R2¼12.20%)
Variable N % OR (95% CI) P OR (95% CI) P
Deprivation quintile 9611 33.5 0.80 0.70
1 (Least deprived) 1126 33.2 1.00 1.00
2 1401 33.5 1.01 0.92 1.12 1.04 0.94 1.15
3 1612 33.3 1.00 0.91 1.10 1.02 0.92 1.13
4 2215 33.0 0.99 0.91 1.08 0.98 0.89 1.08
5 (Most deprived) 3257 33.9 1.03 0.95 1.12 1.02 0.93 1.11
Sex 9611 33.5 0.38
Female 4258 32.1 1.00
Male 5353 34.6 1.02 0.97 1.08
Age group 9611 33.5 o0.001
o60 1707 46.4 1.00
60–69 3140 41.3 0.85 0.78 0.92
70–79 3330 32.5 0.66 0.61 0.72
80þ 1434 19.9 0.50 0.45 0.55
Year of diagnosis 9611 33.5 o0.001
2006 1857 33.6 1.00
2007 1865 32.7 0.95 0.88 1.04
2008 1865 31.9 0.89 0.81 0.97
2009 2060 35.1 1.11 1.00 1.23
2010 1964 34.1 1.11 1.00 1.25
Comorbidity score 9611 33.5 0.004
0 1422 35.5 1.00
1–2 1042 29.5 0.92 0.83 1.02
3þ 228 24.4 0.79 0.66 0.94
Missing 3657 35.9 0.96 0.88 1.05
Unavailable 3262 32.4 0.85 0.77 0.93
GP referral 9611 33.5 o0.001
No 3262 24.6 1.00
Yes 6349 41.1 1.66 1.57 1.75
Stage 9611 33.5 o0.001
I 370 31.2 1.00
II 234 42.4 1.44 1.16 1.80
III 1206 53.1 2.24 1.91 2.63
IV 1259 33.5 1.17 1.00 1.36
missing 6542 31.2 1.45 1.24 1.69
Performance status 9611 33.5 o0.001
0 832 45.2 1.00
1–2 2375 48.8 1.39 1.24 1.56
3–4 387 17.8 0.52 0.44 0.61
Missing 6017 30.3 0.88 0.77 1.00
Histological subtype 9611 33.5 o0.001
Adenocarcinoma 1508 33.8 1.00
Squamous cell 2509 48.0 1.73 1.59 1.89
Large cell 326 42.5 1.45 1.24 1.70
Non-small cell 2269 48.7 1.88 1.72 2.05
Other (specified) 267 23.1 0.59 0.51 0.69
Small cell 1562 44.7 1.59 1.44 1.75
Unspecified carcinoma 163 31.4 1.14 0.93 1.40
Neoplasm 1007 11.9 0.39 0.35 0.43
Abbreviations: CCI score¼Charlson comorbidity score; CI¼ confidence interval; IMD¼ Index of Multiple Deprivation; NSCLC¼ non-small cell lung cancer; OR¼odds ratio; PS¼performance
status; SCLC¼ small cell lung cancer; SEP¼ socioeconomic position.
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more deprived lung cancer patients (Forrest, 2013). Treatment
decisions should be clearly documented and should be based on
the clinical guidelines.
Further research. The results from this study suggest that
socioeconomic inequalities in PS statistically explain socio-
economic inequalities in receipt of chemotherapy in the subgroup
of patients whose cancer was staged. However, this staged
subgroup may not be representative of the full regional cohort as
patients within this were more likely to be younger and to receive
treatment. A previous study has shown a socioeconomic gradient
in completeness of data on stage and grade of cancer, which could
be interpreted as inequality in investigative intensiveness (Adams
et al, 2004). It may be that younger patients receive more intensive
investigation and so are more likely to be staged (Adams et al,
2004) and so, although PS may explain inequalities in chemotherapy
in this group, they are a selective cohort. This is a relationship that
needs to be clarified in other data sets, ideally with lower levels of
missing data for stage and PS.
The observed relationship between histological subtype and
receipt of surgery has not been consistently reported (Lu¨chtenborg
et al, 2012) and further studies are also needed to confirm this
association.
It would be useful to look at receipt of radiotherapy by curative
or palliative intent to determine whether there are different
patterns in likelihood of treatment by SEP.
CONCLUSIONS
Socioeconomic inequalities in lung cancer surgery and chemotherapy,
but not in radiotherapy, were found. We have been able to
investigate a number of factors that may be important in the
relationship between SEP and receipt of treatment that have
previously not been well explored; however, the high levels of
missing data limit the conclusions that can be drawn.
Although histological subtype may account for some of the
socioeconomic gradients in surgery, it does not explain it all.
Socioeconomic inequalities in PS did not explain inequalities in
chemotherapy in the full cohort analyses (although it did within
the staged subgroup), and nor did stage or number of
comorbidities, suggesting that other factors are responsible.
Further research is required to investigate the unexplained
variance in treatment rates, exploring factors such as patient
choice, doctor–patient communication of risk and benefit, and
possible system variation by region, hospital and individual
clinician.
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